Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Revive Therapeutics Ltd > 2017 High broken
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(24)
•••
Comment by Bullchart1on Dec 13, 2020 9:06pm
198 Views
Post# 32097095

RE:2017 High broken

RE:2017 High broken
Bullchart1 wrote: And on no news today. Head over to the 2014 and 2015 highs as a target down the road now.




Watch the stop sell orders we have in here. Just might jump up and take them out. 

Expect a follow-up on Phase 3   FDA


Revive Therapeutics Ltd. has appointed Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical adviser to the company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the continuing U.S. Food & Drug Administration (FDA) phase 3 clinical trial to evaluate the safety and efficacy of bucillamine in patients with mild to moderate COVID-19.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities